Tagged with

LFB In the wake of the most recent CSIS meeting, LFB and Sanofi-Aventis announced the intention to collaborate in bioproduction. What are the terms to this agreement and what are the objectives? On April 2010, the sanofi-aventis group and the LFB group have signed a partnership agreement in France and are…

Shire Brazil We asked Mr. Santos regarding his recommendations to help the government innovate, compete, and grow in the pharmaceutical industry here in Brazil on the Human Genetic Therapies side. Is there a different approach required in the specific area of HGT? For HGT, one very important element is the basic regulatory…

Daiichi Sankyo Germany DAIICHI SANKYO in Germany, Austria and Switzerland DAIICHI SANKYO wants to be a Global Pharma Innovator with Germany at the center of this process on the European continent. An example of this development is your manufacturing facility in Pfaffenhofen, a basis to export to more than 50 countries. Can you…

Teva France We have had the chance to interview a number of Teva’s subsidiaries in Europe, and witnessed how each of them has dealt with the strong transformations that the group has experienced in the last four years. For instance, Mr. Dethlefs from Teva Germany highlighted the challenge in harmonizing five different…

Nycomed France Nycomed lost an important patent with Pantoprazole in the middle of 2009, which has undoubtedly warranted some restructuring. What has been the impact of this loss on business in France, and how are you preparing for the future? Losing exclusivity with Pantoprazole is huge as it was 70% of our…

Quintiles Brazil Many international CROs entered Brazil in the past few years, whereas Quintiles made its first move in Brazil in 1996. What was the strategic decision behind entering Brazil at that time, and what does Brazil represent for Quintiles? Brazil is a top 3 priority right now for Quintiles. The first…

Ipsen Brazil In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of the newer international companies to Brazil, and you have been here since ground zero in 2007. What prompted that initial…

UCB Phrama France Historically, UCB Pharma had a much more ‘traditional’ approach to the industry with a broader scope of operations. Recently, the company reoriented in the direction of biopharmaceuticals by moving away from chemicals and divesting from OTCs. As you have worked on the strategy and policy at headquarters in addition to…

Merck Sharp & Dohme (MSD) Malaysia Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger last year with Schering-Plough, MSD has been #1 in the ethical category and we carry a heavy responsibility to remain…

OEP Philippines Mr. Chang, can you please give an overview of the establishment of OEP Philippines and the company’s current activities here? OEP Philippines started by acquiring the operations of Elan Pharma Phils, an Irish company. In 2003, when Elan Pharma decided to dispose of their subsidiary in the Philippines, Mr. Peter…

Boehringer Ingelheim Brazil You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three years, my assignment was to open this company and to integrate it more with Brazil. We have a quite enlightened…

Boehringer Ingelheim Italy The main distinctive point of Boehringer Ingelheim Italy within the group is its business structure, which relies on three different units: Boehringer Ingelheim Spa, Bidachem and Istituto de Angeli. Could you describe the role of each entity together with its contribution to resources and growth? Boehringer Ingelheim itself is responsible…